Real-world management of immune-related adverse events in the community setting

被引：0
|
作者：
Johnson, D. B. [1 ]
Bruno, D. [2 ]
Rioth, M. [3 ]
Zhang, C. [4 ]
Palaia, J. [5 ]
Pisupati, R. [6 ]
Bond, C. [7 ]
Rosenblatt, L. C. [8 ]
Broome, R. G. [9 ]
Teka, M. [10 ]
Kluger, H. [11 ]
机构：
[1] Vanderbilt Univ, Hematol Oncol, Med Ctr, Nashville, TN USA
[2] Case Western Reserve Univ, Med, Univ Hosp, Cleveland, OH USA
[3] Syapse, Med Oncol, San Francisco, CA USA
[4] Syapse, Data Insights, San Francisco, CA USA
[5] BMS Bristol Myers Squibb, Hlth Econ & Outcomes Res, Princeton, NJ USA
[6] Bristol Myers Squibb, Princeton, NJ USA
[7] BMS Bristol Myers Squibb, Epidemiol, Princeton, NJ USA
[8] Bristol Myers Squibb, WW Hlth Econ & Outcomes Res US Market, Lawrenceville, GA USA
[9] Syapse, Clin Abstract, San Francisco, CA USA
[10] Syapse, Insights Analyt, San Francisco, CA USA
[11] Yale Canc Ctr, Oncol, Breast Ctr, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1675
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1582P
引用
收藏
页码：S1268 / S1269
页数：2
相关论文
共 50 条
  • [1] Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events
    Teimouri, Arezou
    Minard, Laura, V
    Scott, Samantha N.
    Daniels, Amanda
    Snow, Stephanie
    CURRENT ONCOLOGY, 2022, 29 (05) : 3104 - 3117
  • [2] Defining real-world criteria for immune-related adverse events (irAEs).
    Singh, Prabhsimranjot
    Brito, Amanda
    Abdulnour, Raja-Elie E.
    Grover, Shilpa
    Yenulevich, Eric
    Stuver, Sherri Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
    Knox, A.
    Cloney, T.
    Janssen, H.
    Solomon, B.
    Alexander, M.
    John, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S1684 - S1684
  • [4] Acknowledging and addressing real-world challenges to treating immune-related adverse events
    von Itzstein, Mitchell S.
    Gerber, David E.
    Bermas, Bonnie L.
    Meara, Alexa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07)
  • [5] Immune-related adverse events associated with checkpoint inhibitors therapy in a real world setting
    Amaral, Teresa
    Eigentler, Thomas
    Caballero, Paloma
    Tampouri, Ioanna
    Lomberg, Diana
    Assi, Zeinab
    Thomas, Ioannis
    Koechel, Ansgar
    Mueller, Alisa
    Kofler, Lukas
    Leiter, Ulrike
    Forschner, Andrea
    Garbe, Claus
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17
  • [6] Real-world characterization of patients with cancer admitted with immune-related adverse events (irAEs).
    Eng, Lawson
    Chen, RuiQui
    Smith, Elliot Charles
    Chan, Sze Wah Samuel
    Hueniken, Katrina
    Brown, M. Catherine
    Majeed, Habeeb
    Ross, Kendra
    Gray, Diana
    Xu, Wei
    Hogg, David
    Sridhar, Srikala S.
    Sacher, Adrian G.
    Leighl, Natasha B.
    Krzyzanowska, Monika K.
    Liu, Geoffrey
    Butler, Marcus O.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [7] Management of immune-related adverse events: A single-center retrospective analysis in a real-world scenario.
    Iacono, Donatella
    Vitale, Maria Grazia
    Cortiula, Francesco
    Macerelli, Marianna
    Cinausero, Marika
    Minisini, Alessandro Marco
    Valent, Francesca
    Tullio, Annarita
    Palmero, Lorenza
    Targato, Giada
    Zara, Diego
    Fasola, Gianpiero
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Consistent Patterns of Immune-Related Adverse Events in Postmortem and Real-World Data on Immune Checkpoint Inhibitors
    Frey, Connor
    MODERN PATHOLOGY, 2025, 38 (04)
  • [9] Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis
    Yang, Yana
    Li, Linman
    Tian, Jing
    Ma, Linwen
    Wu, Yaoxin
    Luo, Qian
    Luo, Yan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [10] Management of immune-related adverse events
    Princk, Marika Henriette
    Pervan, Mascha
    Riedl, Jorg
    GYNAKOLOGIE, 2023, 56 (04): : 253 - 259
12345